Key Takeaway
Saxenda for weight loss in 2026. How liraglutide works, clinical trial results, daily injection routine, side effects, cost, and how it compares to Wegovy and Mounjaro.
Saxenda for weight loss was the first GLP-1 receptor agonist approved specifically for chronic weight management, earning FDA approval in December 2014. While newer medications like semaglutide and tirzepatide have since captured the spotlight with more impressive weight loss results, Saxenda (liraglutide 3.0 mg) remains an option for certain patients and still holds a place in obesity medicine. Understanding where Saxenda fits in the current treatment space helps patients and physicians make informed decisions.
At FormBlends, we help patients evaluate all available options. This guide covers how Saxenda works, what the clinical data shows, practical considerations, and how it compares to the newer medications that have largely superseded it.
Overview: What Is Saxenda?
Saxenda is the brand name for liraglutide at a 3.0 mg dose, manufactured by Novo Nordisk. compounded formulations of the active ingredient at a lower dose (1.2 mg and 1.8 mg) is sold as Victoza for type 2 diabetes. Liraglutide is a GLP-1 receptor agonist, meaning it mimics the incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and improve blood sugar regulation.
Key facts about Saxenda:
- Administration: Daily subcutaneous injection (compared to weekly for Wegovy and Mounjaro)
- Maximum dose: 3.0 mg daily
- Half-life: Approximately 13 hours (much shorter than semaglutide at 7 days or tirzepatide at 5 days)
- FDA approval: Approved for adults with BMI 30+ or BMI 27+ with a weight-related comorbidity. also approved for adolescents 12 and older
How Saxenda Works
Liraglutide activates GLP-1 receptors in the brain, gut, and pancreas. The mechanisms are similar to newer GLP-1 medications but operate with a shorter-acting profile:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Appetite Suppression
Like all GLP-1 agonists, liraglutide acts on hypothalamic receptors to reduce hunger and increase feelings of satiety. Patients on Saxenda report eating smaller meals and experiencing fewer cravings. The appetite effect is real but generally described as less dramatic than what patients experience on semaglutide or tirzepatide at therapeutic doses.
Delayed Gastric Emptying
Liraglutide slows stomach emptying, extending the feeling of fullness after meals. This effect contributes to reduced caloric intake but also explains common GI side effects like nausea.
Blood Sugar Regulation
Liraglutide enhances glucose-dependent insulin secretion and suppresses glucagon. For patients with pre-diabetes or early type 2 diabetes, Saxenda can improve glycemic control alongside weight loss.
What Saxenda Does NOT Do
Unlike tirzepatide (Mounjaro), Saxenda doesn't activate GIP receptors. It works through a single incretin pathway. This is believed to be one reason its weight loss results are more modest than dual-agonist medications.
Clinical Trial Results
The evidence for Saxenda comes from the SCALE (Satiety and Clinical Adiposity -- Liraglutide Evidence) trial program :
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →SCALE Obesity[1] and Prediabetes
The largest trial enrolled 3,731 adults with obesity or overweight. After 56 weeks:
| Metric | Saxenda 3.0 mg | Placebo |
|---|---|---|
| Average weight loss | 8.0% | 2.6% |
| Participants losing 5%+ | 63.2% | 27.1% |
| Participants losing 10%+ | 33.1% | 10.6% |
| Average weight lost (lbs) | ~18.3 lbs | ~5.7 lbs |
SCALE Diabetes
In patients with type 2 diabetes, liraglutide 3.0 mg produced an average weight loss of 6.0% compared to 2.0% for placebo, along with significant A1c improvements.
SCALE Maintenance
Patients who had already lost at least 5% of body weight through calorie restriction maintained more weight loss with liraglutide compared to placebo, and some continued to lose additional weight.
Putting the Numbers in Context
Saxenda's average weight loss of 5 to 8% was considered clinically meaningful when it was approved in 2014 and was a significant improvement over older medications. But these results are substantially lower than semaglutide (approximately 15%) and tirzepatide (15 to 22.5%), which has shifted Saxenda from a first-line option to a more niche role.
Dosing: The Daily Titration Schedule
Saxenda uses a 5-week titration schedule, increasing by 0.6 mg per week:
| Week | Daily Dose | Purpose |
|---|---|---|
| Week 1 | 0.6 mg | Initial tolerability |
| Week 2 | 1.2 mg | Gradual increase |
| Week 3 | 1.8 mg | Approaching therapeutic dose |
| Week 4 | 2.4 mg | Near-maximum dose |
| Week 5 onward | 3.0 mg | Full therapeutic dose |
The daily injection must be given at approximately the same time each day. Injection sites are the same as other subcutaneous medications: abdomen, thigh, or upper arm. Rotate sites daily.
A key practical difference: Saxenda requires a daily injection, which means 365 injections per year compared to 52 for weekly medications like Wegovy or Mounjaro. This daily routine is manageable for many patients but is clearly less convenient.
Side Effects
Common Side Effects
| Side Effect | Frequency |
|---|---|
| Nausea | 39% |
| Diarrhea | 21% |
| Constipation | 19% |
| Vomiting | 16% |
| Headache | 14% |
| Decreased appetite | 10% |
| Injection site reaction | 14% |
| Fatigue | 8% |
| Dizziness | 7% |
Approximately 9.8% of Saxenda patients in clinical trials discontinued due to adverse events, which is higher than the discontinuation rate seen with tirzepatide (4 to 7%) .
Serious Side Effects
- Pancreatitis: Rare but reported. Seek immediate care for severe, persistent abdominal pain.
- Gallbladder disease: Gallstones and cholecystitis risk increases with rapid weight loss.
- Thyroid tumors: Boxed warning based on rodent studies. Contraindicated in patients with personal or family history of MTC or MEN 2.
- Increased heart rate: Liraglutide has been associated with a mean resting heart rate increase of 2 to 3 beats per minute. Patients with cardiovascular conditions should be monitored.
- Suicidal ideation: Rare reports have been noted. Patients should report any mood changes to their physician .
Cost and Insurance
| Access Route | Monthly Cost | Notes |
|---|---|---|
| Saxenda retail (no insurance) | $1,300 - $1,500 | 30-day supply of daily injections Contact provider for current pricing |
| Saxenda with insurance | $25 - $500 | Coverage varies widely by plan |
| Saxenda savings card | $25+ (with commercial insurance) | Novo Nordisk offers copay savings for eligible patients |
Saxenda costs roughly the same as or more than Wegovy and Mounjaro at retail, while producing less weight loss. This cost-effectiveness gap is one reason many physicians and patients prefer the newer medications.
Saxenda vs. Newer Medications
| Feature | Saxenda (Liraglutide) | Wegovy (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Injection frequency | Daily | Weekly | Weekly |
| Average weight loss | 5-8% | ~15% | 15-22.5% |
| Nausea rate | 39% | 44% | 24-31% |
| Discontinuation rate (side effects) | ~10% | ~7% | 4-7% |
| Monthly retail cost | $1,300-$1,500 | $1,300-$1,400 | $1,050-$1,200 |
| Compounded available | Less commonly | Yes ($179-$399) | Yes ($199-$449) |
| Cardiovascular outcome data | LEADER trial (diabetes. positive) | SELECT trial[2] (positive) | Pending |
When Saxenda Might Still Make Sense
Despite being outperformed by newer options, Saxenda may be appropriate in specific situations:
- Insurance coverage: Some plans cover Saxenda but not Wegovy or Zepbound. If Saxenda is the only covered GLP-1 option, it still provides meaningful benefits.
- Adolescent patients: Saxenda was one of the first GLP-1 medications approved for patients aged 12 and older with obesity.
- Patient preference for a known medication: Saxenda has the longest real-world track record of any GLP-1 weight loss medication (approved since 2014).
- Intolerance to newer medications: Rare cases where a patient can't tolerate semaglutide or tirzepatide may respond differently to liraglutide.
- Combination with other approaches: Some physicians use Saxenda as part of a multi-medication strategy or as a bridge to other treatments.
Frequently Asked Questions
Is Saxenda still worth taking in 2026?
Saxenda remains FDA-approved and produces clinically meaningful weight loss (5 to 8%). But for most patients, newer options like semaglutide and tirzepatide offer significantly greater weight loss, more convenient dosing, and similar or better side effect profiles at comparable costs. Saxenda is best considered when newer alternatives aren't available or not tolerated Mounjaro vs alternatives.
Why was Saxenda popular before Wegovy and Mounjaro?
Before semaglutide 2.4 mg (Wegovy) was approved in 2021, Saxenda was the only GLP-1 medication approved for weight loss. Its 5 to 8% average weight loss was a significant improvement over older pills like phentermine and orlistat. The field has simply advanced beyond what liraglutide[1] can deliver.
Can I switch from Saxenda to Mounjaro or Wegovy?
Yes. Many patients have successfully transitioned from Saxenda to newer GLP-1 medications. Your physician will determine the appropriate starting dose of the new medication. You don't need to taper off Saxenda before switching. you simply stop one and start the other.
Does Saxenda require a daily injection forever?
As with all GLP-1 medications for weight loss, the benefits depend on continued use. Stopping Saxenda typically leads to weight regain, as shown in the SCALE Maintenance trial. The need for daily injections indefinitely is one of the practical drawbacks compared to weekly options.
Is Saxenda available as a compounded medication?
Liraglutide is less commonly compounded than semaglutide or tirzepatide. Most compounding pharmacies focus on the newer, more popular molecules. This limits the affordability advantage that compounding offers for other GLP-1 medications.
Medical References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Getting Started with FormBlends
If you're considering GLP-1 therapy for weight loss, we can help you determine which medication gives you the best chance of success. For most patients, that means semaglutide or tirzepatide rather than Saxenda. At FormBlends, our physicians evaluate your individual situation and recommend the option that aligns with your health profile, goals, and budget.
Start your free online assessment today to discuss your options with a licensed physician.